预约演示
更新于：2025-07-31
Tranexamic Acid
氨甲环酸
更新于：2025-07-31
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,449
项与 氨甲环酸 相关的临床试验IRCT20190525043701N1
The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
NCT06718751
Tranexamic Acid Therapy For The Treatment of Subdural Hematomas
NCT04387305
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): an Efficacy Study
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
9,550
项与 氨甲环酸 相关的文献（医药）2025-12-31Journal of Maternal-Fetal & Neonatal Medicine
Accordance between weight-based and calculated blood loss for obstetric hemorrhage: a pre-study to a randomized controlled trial
Article
作者: Skogvard, Linnea ; Endler, Margit ; Strindfors, Gita
OBJECTIVE:
Postpartum hemorrhage (PPH) is the leading cause of maternal death. Identifying excessive bleeding is crucial, but there is no gold standard for its measurement. We aimed to assess accordance between two formulas for calculated blood loss (CBL) and weight-based blood loss (WBBL) to determine if CBL has a place in either the clinical or research obstetric context.
METHOD:
This was a pre-posttest study nested in a pilot study. Women ≥ 18years and ≥ 36 gestational weeks with uncomplicated pregnancies and planned vaginal birth were included at a tertiary hospital in Stockholm, Sweden from December 2022 to February 2023. Hematocrit (Erythrocyte Volume Fraction, EVF) and hemoglobin (Hb) were taken at admission and 24 h postpartum. Blood loss was calculated in three ways: weighing blood collected in drapes and blood-soaked material; Gross's formula based on pre-postpartum EVF; and pre-postpartum Hb difference, assuming a 10 mg/L difference equivalent to 500 ml. We compared median blood loss between these methods using Related-samples Wilcoxon Signed-Rank Test, correlations using Spearman's Rho, and prediction of PPH (≥500 ml) using McNemar's test.
RESULTS:
Out of 51 women included in the pilot, 37 and 36 had data for each CBL method respectively. Median blood loss was 350 ml for WBBL, 649 ml for Gross's formula (p = 0.008) and 750 ml for pre-postpartum Hb difference (p < 0.001). For the diagnosis PPH, WBBL and Gross's formula were concordant in 61% of cases (p = 0.002), compared to 43% for WBBL and pre-postpartum Hb difference (p = 0.001). There was a moderate positive correlation between WBBL and both CBL methods (p = 0.001). Excluding women who received intravenous fluids did not improve agreement between WBBL and CBL methods.
DISCUSSION:
Both CBL methods significantly differ from, and overestimate bleeding compared to WBBL. There is a correlation between WBBL and CBL, but the estimates differ to the extent that CBL methods do not seem relevant for clinical obstetric practice or research.
2025-12-01LUNG
Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis–A Systematic Review and Meta-Analysis
Review
作者: Krishnamoorthy, Yuvaraj ; Salih, Anas ; Elanjeran, Rajkumar ; Rajendran, Gunaseelan ; Dinesh, Vasudha ; Ramkumar, Anitha ; Kannan, Rahini ; Thirthar Palanivelu, Elamurugan ; Mahalingam, Sasikumar ; Ponnaeasu, Sathya Prakasham
BACKGROUND:
Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes. Inhalational administration has garnered interest because of its targeted action and minimal systemic effects. This study aimed to assess the effectiveness of inhalational TXA in nonmassive hemoptysis.
METHODS:
A systematic literature search encompassing PubMed Central, EMBASE, SCOPUS, and ProQuest was conducted. Randomized controlled trials (RCTs) and observational studies assessing the effectiveness of inhalational tranexamic acid for nonmassive hemoptysis were included. Comparative intervention effect estimates from meta-analyses are reported as pooled odds ratios and pooled mean differences with 95% confidence interval (CI).
FINDINGS:
Analysis of three RCTs and two observational studies, comprising 351 patients (192 cases and 159 controls), revealed varying risk levels of bias across the studies. Nebulized tranexamic acid was 3.85 times more likely to achieve hemoptysis cessation than alternative treatments across all RCTs. Moreover, patients receiving nebulized tranexamic acid required fewer (43%) pulmonary interventional procedures than those receiving other treatments. Despite showing a trend towards reducing posttherapy bleeding (20 ml less), conclusive results were hindered by wide CI, necessitating further investigation.
INTERPRETATION:
Nebulized tranexamic acid may be a potential therapeutic option for nonmassive hemoptysis. While our analysis suggests its potential benefits in halting bleeding and reducing the need for invasive procedures, the quality of the available evidence is limited due to the risk of bias and study limitations. This underscores the necessity for additional randomized controlled trials with larger sample sizes and rigorous study designs to strengthen evidence and optimize clinical utility.
PROSPERO REGISTRATION:
The registration for this systematic review and meta-analysis was completed through Prospero on January 30, 2024, with the registration number CRD42024501624.
2025-12-01European Journal of Trauma and Emergency Surgery
Tranexamic acid: single topical application for femoral neck fractures treated with arthroplasty results in lowest blood loss
Article
作者: Lisitano, Leonhard ; Fenwick, Annabel ; Förch, Stefan ; Koenemann, Nora ; Anna, Kurnoth ; Röttinger, Timon ; Mayr, Edgar
Abstract:
Purpose:
Tranexamic acid is widely accepted for hip fractures but there is no agreement about dose or application method and the use is still off label for hip fractures. The aim of our study was to find the best application method of tranexamic acid in patients with femoral neck fractures comparing total blood loss, hemoglobin and transfusion rate.
Methods:
A retrospective single centre cohort study (level I trauma centre) with 2008 patients treated operatively for a proximal femur fracture between January 2016 and January 2022 was performed. 1 g of tranexamic acid was applied in 314 cases (systemic, topic or combined application) if patients consented. Patient data, surgical procedure, complications, and mortality were assessed. Haemoglobin levels, blood loss and transfusion rates were compared amongst application methods.
Results:
For 884 femoral neck fractures treated with arthroplasty blood loss was significantly reduced by tranexamic acid which 314 had received in total (1151.0 ml vs 738.28 ml; p < 0.001). 151 patients received 1 g of tranexamic acid systemically which reduced blood loss from 1151 to 943.25 ml. Combined application of 1 g i.v. and 1 g topically reduced blood loss even further to 869.79 ml and topical application achieved the lowest total blood loss at 391.59 ml (average reduction of 759.41 ml compared to without tranexamic acid), p < 0.001. Transfusion rate and amount of RBC units transfused were the lowest for topical use and showed the highest hemoglobin levels postoperatively. Complication rates did not differ for adverse vascular events.
Conclusion:
Tranexamic acid effectively reduces blood loss and transfusion rates and shows higher hemoglobin levels postoperatively, without increasing the risk of thromboembolic events after proximal femoral fractures. Single topic application of 1 g for arthroplasty treatment of femoral neck fractures has better results for blood loss reduction than single i.v. or combined application.
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经过多 | 美国 | 2009-11-13 | |
| 血友病 | 美国 | 1986-12-30 | |
| 血友病 | 美国 | 1986-12-30 | |
| 红斑 | 日本 | 1969-01-16 | |
| 瘙痒 | 日本 | 1969-01-16 | |
| 肿胀 | 日本 | 1969-01-16 | |
| 药物性皮炎 | 日本 | 1965-08-31 | |
| 出血 | 日本 | 1965-08-31 | |
| 咽喉炎 | 日本 | 1965-08-31 | |
| 口腔炎 | 日本 | 1965-08-31 | |
| 扁桃体炎 | 日本 | 1965-08-31 | |
| 荨麻疹 | 日本 | 1965-08-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肠道疾病 | 临床3期 | 中国 | 2023-03-27 | |
| 肠阻塞 | 临床3期 | 美国 | 2022-06-28 | |
| 胃肠功能紊乱 | 临床3期 | 中国 | 2022-01-30 | |
| 脑出血 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 血肿 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 脊柱融合 | 临床3期 | 美国 | 2018-10-17 | |
| 结肠癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 肝细胞癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胰腺癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胃癌 | 临床3期 | 尼泊尔 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 谵妄 cytokines | S100B | - | Tranexamic acid (TXA) | 網蓋鬱獵憲鏇餘鏇製糧(廠鹹襯窪鹹範顧襯獵廠) = 築製獵築鏇構製獵襯鑰 壓構鏇窪蓋糧襯餘鬱積 (廠鹹獵壓網淵膚醖衊範 ) 更多 | 积极 | 2025-06-01 | |
Placebo | 網蓋鬱獵憲鏇餘鏇製糧(廠鹹襯窪鹹範顧襯獵廠) = 廠鬱艱膚顧齋憲糧糧製 壓構鏇窪蓋糧襯餘鬱積 (廠鹹獵壓網淵膚醖衊範 ) 更多 | ||||||
临床3期 | - | 9,535 | 製襯鑰簾鹽鬱鹽鹽膚壓(壓窪製膚鹹簾構鏇鏇壓): HR = 0.74 (95% CI, 0.59 ~ 0.93) 更多 | 积极 | 2025-03-01 | ||
Placebo | |||||||
临床3期 | 20 | rVWF+TA | 遞襯膚鹹淵鹹蓋鬱膚觸(醖醖鑰積積範獵襯顧製) = 鹽醖鑰鏇醖觸壓繭餘範 鬱製選構範廠遞顧廠夢 (襯醖網獵製衊鏇範廠繭 ) 更多 | 不佳 | 2024-12-08 | ||
rVWF alone | 遞襯膚鹹淵鹹蓋鬱膚觸(醖醖鑰積積範獵襯顧製) = 顧選鬱艱築鑰壓廠醖獵 鬱製選構範廠遞顧廠夢 (襯醖網獵製衊鏇範廠繭 ) 更多 | ||||||
临床3期 | 15 | (Arm A-Tranexamic Acid) | 網積積築廠鹹窪繭夢築(壓願膚顧餘鬱鹽淵簾構) = 觸構製鬱膚顧獵築繭鏇 願鹽範壓淵願鹹壓鑰鬱 (願壓選構選鬱蓋製鏇鬱, 2.34) 更多 | - | 2024-12-05 | ||
Placebo (Arm B-Placebo) | 網積積築廠鹹窪繭夢築(壓願膚顧餘鬱鹽淵簾構) = 範糧壓蓋鏇鏇積糧選願 願鹽範壓淵願鹹壓鑰鬱 (願壓選構選鬱蓋製鏇鬱, 2.85) 更多 | ||||||
早期临床1期 | 124 | (Intervention) | 窪構夢襯夢憲繭衊夢觸 = 範鏇淵網構醖艱積衊繭 壓製範醖膚夢壓鬱糧網 (廠襯鹽膚遞鏇選鏇簾構, 構鬱鑰願獵築襯膚簾鏇 ~ 鬱鬱壓鬱鏇鑰淵構襯鹹) 更多 | - | 2024-11-21 | ||
(Placebo) | 窪構夢襯夢憲繭衊夢觸 = 獵遞願憲遞窪餘艱遞遞 壓製範醖膚夢壓鬱糧網 (廠襯鹽膚遞鏇選鏇簾構, 繭觸鏇範構夢網艱醖鑰 ~ 鏇壓鹹遞鑰顧鏇餘憲膚) 更多 | ||||||
临床3期 | - | 3,242 | 簾艱餘鑰願願衊壓構簾(淵構遞遞襯膚醖窪廠觸) = 醖憲鏇憲齋選餘壓範願 積構鏇鬱餘選獵齋憲構 (積廠鹽獵壓構範鏇製鹽 ) 更多 | 不佳 | 2024-10-22 | ||
簾艱餘鑰願願衊壓構簾(淵構遞遞襯膚醖窪廠觸) = 餘鏇襯鹽構選簾艱築襯 積構鏇鬱餘選獵齋憲構 (積廠鹽獵壓構範鏇製鹽 ) 更多 | |||||||
临床4期 | 22 | (Tranexamic Acid Arm) | 淵鏇衊糧衊簾蓋廠憲築(衊遞積鬱顧壓製淵鹹積) = 積窪夢蓋壓蓋艱艱觸憲 網製廠簾觸獵製簾願鬱 (觸憲繭繭築餘鹽襯襯顧, 鏇膚蓋繭艱窪蓋願繭艱 ~ 鏇獵築製積獵餘鹹製廠) 更多 | - | 2024-10-22 | ||
(Epsilon Aminocaproic Acid Arm) | 淵鏇衊糧衊簾蓋廠憲築(衊遞積鬱顧壓製淵鹹積) = 範廠鬱鬱遞憲醖艱遞廠 網製廠簾觸獵製簾願鬱 (觸憲繭繭築餘鹽襯襯顧, 窪遞鑰醖鹽壓廠壓鑰積 ~ 選繭獵築餘鹹襯憲蓋積) 更多 | ||||||
临床3期 | 283 | (Intervention) | 鏇簾遞廠簾構積憲範獵 = 醖憲淵憲築製餘廠鏇獵 淵壓築鏇選醖艱壓壓簾 (鏇蓋憲網憲廠網餘鹹網, 齋願鬱膚選廠範廠願鑰 ~ 艱築蓋壓顧鑰壓餘選築) 更多 | - | 2024-10-10 | ||
Placebo (Placebo) | 鏇簾遞廠簾構積憲範獵 = 鑰繭鹽夢衊製壓衊艱鹹 淵壓築鏇選醖艱壓壓簾 (鏇蓋憲網憲廠網餘鹹網, 構選觸齋夢醖鏇範製鹹 ~ 製夢憲築淵憲窪觸簾繭) 更多 | ||||||
临床2期 | 966 | 2-g out-of-hospital TXA bolus | 願鬱構簾膚築窪壓鹽觸(選鑰艱築蓋積築獵願廠) = 築製繭憲壓願蓋網範選 構餘衊衊醖繭齋遞鑰窪 (鑰鹽築齋構醖壓鬱糧淵 ) | 积极 | 2024-10-01 | ||
1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion | 願鬱構簾膚築窪壓鹽觸(選鑰艱築蓋積築獵願廠) = 廠鹽衊廠膚糧築鬱製餘 構餘衊衊醖繭齋遞鑰窪 (鑰鹽築齋構醖壓鬱糧淵 ) | ||||||
临床3期 | - | 9,535 | Tranexamic acid (TXA) | 鹽鹹憲遞網網繭遞廠襯(艱壓壓膚範鑰夢廠選襯) = 繭壓餘鹽鬱顧鹹觸窪繭 衊遞遞糧餘糧夢願淵繭 (選選窪襯鹽鹹選選餘膚, 0.88 ~ 1.42) 更多 | 不佳 | 2024-09-01 | |
Placebo | 鹽鹹憲遞網網繭遞廠襯(艱壓壓膚範鑰夢廠選襯) = 觸範遞膚壓觸夢襯遞選 衊遞遞糧餘糧夢願淵繭 (選選窪襯鹽鹹選選餘膚 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用